News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides a revenue breakdown for Netease Inc Sponsored ADR (LSE:0K6G), highlighting its top-performing segment and geographical contribution. In the last fiscal year, the company generated $16.10 billion USD, with $12.82 billion USD coming from Games and Related Value-added Services. China was the …
Brookmont Capital Management significantly increased its holdings in NetEase, Inc. (NASDAQ:NTES) by 137.1% during the second quarter, bringing its total investment to $3.27 million. This makes NetEase the fund's 19th largest holding, representing 1.8% of its portfolio. Despite some recent analyst downgrades, NetEase maintains …
NetEase, Inc. (NTES) has filed a quarterly Form 13F as an institutional investment manager, signed by CEO William Lei Ding. The report discloses two line-item positions with an aggregate value of $765,380,098, indicating its total U.S. equity holdings. The filing also clarifies that no …
NetEase, Inc. (NTES) reported that its Vice President of Finance, Mo Bin, received a grant of 716 American Depositary Shares (ADSs) as compensation in the form of restricted stock units (RSUs). These RSUs had a performance-based vesting condition satisfied on August 11, 2026, and …
Atea Pharmaceuticals (AVIR.US) is scheduled to release its earnings report after the market closes on August 12. This announcement provides investors with the specific date to anticipate the company's financial performance update.
Morgan Stanley has increased its price target for Atea Pharmaceuticals (AVIR) to $7 from $6, while reiterating an "Equalweight" rating on the stock. This adjustment comes amidst recent company news, including Atea's Q2 2026 earnings call and positive topline results from its C-BEYOND Phase …
Earnings Call Insights: Atea Pharmaceuticals (AVIR) Q2 2026 MANAGEMENT VIEW * "The positive top line results from C-BEYOND, our Phase III trial evaluating the combination of bemnifosbuvir for the treatment of hepatitis C in North America represents a significant milestone for Atea" (Founder, Chairman, …
ATEA Pharmaceuticals ($AVIR) reported its Q2 2026 earnings, posting a loss of -$0.41 per share, significantly beating analyst estimates of -$0.57. The company's revenue matched estimates at $0. The article also details recent hedge fund activity for AVIR, showing institutional investors adding and decreasing …
This article analyzes Netease Inc. (NTES) with AI-generated trading strategies and risk zones. It highlights mixed sentiment, an exceptional short setup with a 35.8:1 risk-reward ratio, and provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The …
Atea Pharmaceuticals has filed its Q2 2026 Form 10-Q report, detailing its financial status, including 80,204,699 shares outstanding as of August 10, 2026. The company is actively pursuing two antiviral programs: the C-FORWARD Phase 3 clinical trial for Hepatitis C (HCV) with BEM/RZR, and …
Atea Pharmaceuticals (NASDAQ:AVIR) announced its quarterly earnings, reporting an EPS of ($0.41), surpassing the consensus estimate of ($0.56) by $0.15. The company's shares traded at $5.06, and it has a market capitalization of approximately $405 million. Analyst sentiment is divided, with one Strong Buy …
Atea Pharmaceuticals reported Q2 2026 financial results, including a net loss of $32.9 million, and provided a business update highlighting progress in its viral hepatitis pipeline. The Phase 3 C-BEYOND trial for its HCV regimen (BEM/RZR) met primary and secondary non-inferiority endpoints with a …
Atea Pharmaceuticals announced its second-quarter 2026 financial results, highlighting positive Phase 3 C-BEYOND trial results for BEM/RZR in treating HCV, which met primary and secondary endpoints. The company also provided updates on its C-FORWARD trial, expected in early Q1 2027, and advancements in its …
Search by ticker symbol or company name and select a result to open its chart.